A Phase 1/2 Study of AZD9574 Alone and With Other Anti-Cancer Drugs in People with Glioma


Full Title

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (CERTIS1)


Researchers want to find the best dose of AZD9574 that can be given with temozolomide. The people in this study have glioma that has a mutation (change or variant) in an IDH gene. They have cancer that came back or keeps growing even after treatment. Both AZD9574 and temozolomide are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have glioma that has an IDH1 or IDH2 mutation.
  • Have a tumor that came back or keeps growing even though you had chemotherapy and radiation therapy.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Lauren Schaff’s office at 212-610-0485.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory


ClinicalTrials.gov ID